Seaport Therapeutics, Inc. Common Stock
- SPTX
- NASDAQ
- Biotechnology
- Neuropsychiatric Treatments
- Clinical-Stage Biotech
$17.79
Today −0.22%Quote Oct 19, 2026, 08:00 PM UTC
−16.83%over the last month
Max drawdown −28.2%From 1-month high −20.5%3 months −15.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
58
Founded
2024
Market value
$952.3M
Quote Oct 19
Floor
$17.15
3.6% below price
Resistance
$18.78
5.6% above price
Price vs analyst targets
1 analyst
Lowest target
$28.00Highest target
$50.00
$28.00Highest target
$50.00
- Price $17.79
- Average target $38.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 116% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SPTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free